A phase i study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous azacitidine and its pharmacokinetics in patients with severe renal impairment

Pharmacotherapy

Volumn 34, Issue 5, 2014, Pages 440-451

  Laille, Eric ^a   Goel, Sanjay ^b   Mita, Alain C ^c   Gabrail, Nashat Y ^d   Kelly, Kevin ^c   Liu, Liangang ^a   Songer, Stephen ^a   Beach, Charles L ^a  

^a CELGENE CORPORATION   (United States)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d Gabrail Cancer Center   (United States)

Author keywords

azacitidine; dose proportionality; myelodysplasia; pharmacokinetics; renal impairment; solid tumor

Indexed keywords

AZACITIDINE; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE PROPORTIONALITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PLASMA HALF LIFE; RANDOMIZED CONTROLLED TRIAL; SEVERE RENAL IMPAIRMENT; SINGLE DRUG DOSE; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; CLINICAL TRIAL; COMPLICATION; HEMATOLOGIC NEOPLASMS; KIDNEY FAILURE; METABOLISM; MIDDLE AGED; NEOPLASMS; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NEOPLASMS; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84899059777     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1371     Document Type: Article

References (17)

1. Christman JK, Mendelsohn N, Herzog D, Schneiderman N,. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer Res 1983; 43: 763-9. (Pubitemid 13193877)
2. Jones PA, Taylor SM, Wilson VL,. Inhibition of DNA methylation by 5-azacytidine. Recent Results Cancer Res 1983; 84: 202-11.
3. Christman JK,. 5-Azacytidine and 5-aza-2â€-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21: 5483-95. (Pubitemid 34983483)
4. ® prescribing information. Celgene Corporation, Summit, NJ 2011; Revised August 2011.
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-32.
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-9.
7. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-40. (Pubitemid 34525728)
8. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895-903. (Pubitemid 46630737)
9. Rudek MA, Zhao M, He P, et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 2005; 23: 3906-11. (Pubitemid 46218693)
10. Deschler B, de Witte T, Mertelsmann R, Lubbert M,. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006; 91: 1513-22. (Pubitemid 44736118)
11. Ria R, Moschetta M, Reale A, et al. Managing myelodysplastic symptoms in elderly patients. Clin Interv Aging 2009; 4: 413-23.
12. Ji B, Zhang S, Gong L, et al. The risk factors of mild decline in estimated glomerular filtration rate in a community-based population. Clin Biochem 2013; 46 (9): 750-4.
13. Erler A, Beyer M, Petersen JJ, et al. How to improve drug dosing for patients with renal impairment in primary care-a cluster-randomized controlled trial. BMC Fam Pract 2012; 13: 91.
14. Israili ZH, Vogler WR, Mingioli ES, et al. The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion. Cancer Res 1976; 36: 1453-61.
15. Troetel WM, Weiss AJ, Stambaugh JE, et al. Absorption, distribution, and excretion of 5-azacytidine (NSC-102816) in man. Cancer Chemother Rep 1972; 56: 405-11.
16. Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011; 29: 2521-7.
17. Marcucci G, Silverman L, Eller M, Lintz L, Beach CL,. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 2005; 45: 597-602. (Pubitemid 40562951)